3SBio Inc (1530)

Hong Kong
5.40
-0.05(-0.92%)
  • Volume:
    2,829,255
  • Bid/Ask:
    5.40/5.41
  • Day's Range:
    5.38 - 5.52

1530 Overview

Prev. Close
5.45
Day's Range
5.38-5.52
Revenue
7.49B
Open
5.49
52 wk Range
4.72-12.3
EPS
0.7
Volume
2,829,255
Market Cap
13.17B
Dividend (Yield)
0.20
(3.70%)
Average Vol. (3m)
7,188,956
P/E Ratio
7.68
Beta
0.93
1-Year Change
-30.04%
Shares Outstanding
2,438,845,412
Next Earnings Date
May 25, 2022
What is your sentiment on 3SBio?
or
Market is currently closed. Voting is open during market hours.

3SBio Inc News

3SBio Inc Company Profile

3SBio Inc Company Profile

Employees
5292
Market
Hong Kong

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People’s Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana–Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People’s Republic of China.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • JPM Axes 3SBIO TP to $10; Rated Overweight
    0
    • Macquarie Adds 3SBIO TP to $13.08; Rated ***Outperform***
      0